Abstract Cancer is a global burden that is increasingly rising accounting for a quarter of all deaths in Europe. Despite the great efforts of biomedical research the mortality rate is still too high and so are the related costs. Psychosocial Genomics Research Program in Oncology (PSGPO) aims to integrate psychological and biomedical knowledge on the base of neuroscientific findings, genomic research and mind-body medicine to explore if a new mind-body therapeutic approach can improve quality of life of patients at risk of cancer relapse after the completion of locoregional treatment and adjuvant chemotherapy. To achieve this objective a randomized clinical trial will be carried out. Patients diagnosed with a solid tumor will be recruited at the end of the standard treatment when standard follow-up according to international guidelines begins. Those who will accept the trial will be randomized to a control arm where only standard follow up will be foreseen (A), and an experimental arm where a mind-body therapy (B) will be added to standard follow-up. All patients will be assessed before and after the clinical trial by using both psychological and clinical indicators. Patients will also provide peripheral blood leukocyte samples for genome wide transcriptional profiling, bioinformatic analysis and primer assays analysis developed in order to investigate relevant pathways and genes. We hypothesize the improvement of the therapeutic outcome on quality of life, level of distress perceived, the anxiety and depression in patients treated with a mind-body intervention (MBT-T). The genomic research carried out will clarify the molecular mechanisms underlying the greater therapeutic effects of our intervention.
A Psychosocial Genomics Research Program in Oncology (PSGPO) for Verifying Clinical, Genomic and Epigenetic Effects of Mind-Body Transformations Therapy (MBT-T) in Breast Cancer Patients.
Cozzolino Mauro
Writing – Original Draft Preparation
2016-01-01
Abstract
Abstract Cancer is a global burden that is increasingly rising accounting for a quarter of all deaths in Europe. Despite the great efforts of biomedical research the mortality rate is still too high and so are the related costs. Psychosocial Genomics Research Program in Oncology (PSGPO) aims to integrate psychological and biomedical knowledge on the base of neuroscientific findings, genomic research and mind-body medicine to explore if a new mind-body therapeutic approach can improve quality of life of patients at risk of cancer relapse after the completion of locoregional treatment and adjuvant chemotherapy. To achieve this objective a randomized clinical trial will be carried out. Patients diagnosed with a solid tumor will be recruited at the end of the standard treatment when standard follow-up according to international guidelines begins. Those who will accept the trial will be randomized to a control arm where only standard follow up will be foreseen (A), and an experimental arm where a mind-body therapy (B) will be added to standard follow-up. All patients will be assessed before and after the clinical trial by using both psychological and clinical indicators. Patients will also provide peripheral blood leukocyte samples for genome wide transcriptional profiling, bioinformatic analysis and primer assays analysis developed in order to investigate relevant pathways and genes. We hypothesize the improvement of the therapeutic outcome on quality of life, level of distress perceived, the anxiety and depression in patients treated with a mind-body intervention (MBT-T). The genomic research carried out will clarify the molecular mechanisms underlying the greater therapeutic effects of our intervention.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
